，因为在血—脑之间存在的一种选择性地阻止某些物质通过血液到人脑的“屏障”——血脑屏障，这阻碍了传统药物（太大）通过屏障达到肿瘤细胞，而利用TAT peptide carrier也许就可以解决这一问题。同时这一研究也和杨的对抗凝血剂肝素（Heparin）抑制途径的研究相关联：肝素被用于手术中抗凝血，一般术后会使用肝素酶来逆转这一抗凝作用，但杨尝试利用鱼精蛋白来替代。（2005年杜克大学提出了鱼精蛋白逆转肝素作用可能更安全，生物通注释）。以上这些工作尚属于实验阶段，而且关于为什TAT多肽能进入细胞的机理还未得到完全解释，但杨认为可能与病毒入侵细胞机理相似。 附： Education: Ph.D. Brown University; Biochemistry and Biophysics Affiliations: Elected Fellow of American Association of Pharmaceutical Scientists Representative PublicationsJun-Feng Liang, Maureen E. Connell, Yong T. Li, and Victor C. Yang, “Synthesis and Characterization of Positively Charged t-PA as a Prodrug Using Heparin/Protamine Drug Delivery System.” AAPS PharmSci, 2(1), article 7 (2000) (http://www.pharmsci.org). Jun-Feng Liang, Yong T. Li, and Victor C. Yang, “Biomedical Application of Immobilized Enzymes.” Journal of Pharmaceutical Sciences, 89, 979-990 (2000). Li-Chien Chang, Hsiao-Feng Lee, Zhi-Qiang Yang, and Victor C. Yang, “Low Molecular Weight Protamine (LMWP) as Non-Toxic Heparin/LMWH Antidote. [I]: Preparation and Characterization.” AAPS PharmSci, 3(2) article 17 ; article 18; article 19 (2001) (http://www.pharmsci.org). Yuehua Zhang, Zhi-Qiang Yang, Peter Markland, and Victor C. Yang, “Poly(glutamic acid) Poly(ethylene glycol) Hydrogels Prepared by Photo-Induced Polymerization: Synthesis, Characterization, and Preliminary Release Studies of Protein Drugs” Journal of Biomedical Materials Research, in press (2001).
< 1 > < 2 >
|
